Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia
Unknown status
National Cancer Institute (NCI)
Phase 3
2001-09-01
RATIONALE: Levofloxacin may be effective in reducing fever and controlling other symptoms of
neutropenia in patients who are being treated for cancer. It is not yet known whether
levofloxacin is more effective than cefepime in reducing fever and controlling symptoms of
neutropenia.
PURPOSE: Randomized phase III trial to compare the effectiveness of levofloxacin with that of
cefepime in reducing fever and controlling symptoms of neutropenia in patients who are being
treated for cancer.
Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia
Unknown status
Jonsson Comprehensive Cancer Center
Phase 3
2001-09-01
RATIONALE: Levofloxacin may be effective in reducing fever and controlling other symptoms of
neutropenia in patients who are being treated for cancer. It is not yet known whether
levofloxacin is more effective than cefepime in reducing fever and controlling symptoms of
neutropenia.
PURPOSE: Randomized phase III trial to compare the effectiveness of levofloxacin with that of
cefepime in reducing fever and controlling symptoms of neutropenia in patients who are being
treated for cancer.
Study Comparing the Safety and Efficacy of Piperacillin/Tazobactam to Cefepime in Patients With Hematologic Malignancy or Lymphoma
Completed
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 3
1969-12-31
To compare the safety and efficacy of piperacillin/tazobactam (4 g/500 mg) administered
intravenously every 6 hours to cefepime (2 g) administered intravenously every 8 hours for
the empiric treatment of neutropenic fever in patients with a hematologic malignancy or
lymphoma.
Comparing Ciprofloxacin (CPFX) With Cefepime (CFPM) in Febrile Neutropenic Patients With Hematologic Diseases
Completed
Bayer
Phase 3
2005-04-01
The aim of this study is to investigate whether intravenous ciprofloxacin is as effective as
cefepime for the initial treatment of febrile neutropenia developed in patients with
hematologic diseases.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
